Healthcare Trends and Growth Indicators for Physician Offices/labs in Decentralized Testing and Services

Personalized Diagnostics Are at the Cusp of Transformational Growth

INDUSTRY
Healthcare
SECTOR
Life Sciences

RELEASE DATE
30-Dec-2022
REGION
North America
DELIVERABLE TYPE
Market Research

RESEARCH CODE
PE45-01-00-00-00
SKU
HC03631-NA-MT_27389
Yes
SHARE

Trends and Growth Indicators for Physician Offices/labs in Decentralized Testing and Services
Published on: 30-Dec-2022 | SKU: HC03631-NA-MT_27389

Need more details?

$2,450.00

$1,837.50 save 25 %

DownloadLink
Need more details?

Accelerated reforms due to COVID-19 and technologically advanced sample-in-answer-out portable, web-connected, encrypted devices that provide results in a few minutes changed the diagnostic healthcare industry. Decentralized testing empowers clinicians to make lifesaving decisions for the patient. It shortens supply chain lag time, saves costs of in-person clinical examination, reduces the length of hospital stay and wait lines, and helps improve access to rural and semi-urban settings for timely healthcare intervention.

The next-generation point-of-care diagnostics is at an inflection point and is transforming patient care in emergency, acute, chronic, and specialized care with platforms capable of monitoring/measuring a wide range of disease markers with laboratory precision. The diagnostic innovation of assays for rapid detection, miniaturization of portable devices, and automation of workflows serves the broad spectrum of setting and shift toward hyper-scaling of access and comprehensive test designs.

The study showcases several diagnostic technologies, such as a microfluidic-based hand-held portable device (lab-on-a-chip device) designed to provide atraumatic, end-to-end point-of-care automated and integrated diagnostic solution, with its sample-on-chip preparation and nucleic acid analysis assay.
•     The recent paper-based devices with Nucleic Acid Testing (NAT) have shown great promise for infectious diseases and detection etiology of
infection (bacterial, viral, or fungal) with its cost-effective, bio-compatible, disposable on-site monitoring/testing.
•     Lateral flow devices with sensor technology enable rapid analysis of blood samples for many critical care assays. These include blood
gases/electrolytes, cardiac markers, cholesterol/lipids, coagulation monitoring, glucose monitoring, hematology, infectious diseases,
pregnancy and fertility, tumor/cancer markers, urinalysis, other chemistries (magnesium, lactate, micro-albumin, creatinine), and more.
•     Decentralized clinical diagnostics continue to innovate a wide range of systems and assays with rapid test analyzers, instruments, reagents,
strips, and cartridges. The electronic services complement it with automation, cloud computing, and deep learning for rapid and accurate
results.

Digital technology is accelerating the adoption of decentralization in clinical practice as the workflows integrate with POC at-home systems delivering lab results on smartphones. Integrated, comprehensive diagnostic services are key differentiators for stakeholders, which vary in their offering to enterprises (labs, physician offices, or hospital emergency units) or patients. These services will enhance patient-centered access to care and help physicians close the diagnostic loop of the healthcare continuum.

The regulatory environment analysis of the study provides insight into policies in the US, Europe, and the UK that are currently shaping the implementation of decentralized clinical diagnostics and influencing market adoption.

The study, with an in-depth analysis of the industry environment and its participants, such as clinical laboratories, diagnostic/technology companies, retail, pharmacies, and start-ups, proposes a market model for connected healthcare and the prospective growth opportunities for stakeholders.

Frost & Sullivan predicts the decentralized diagnostic testing market and services to grow exponentially in the next 5 years. This forecast
considers structural shifts and economic uncertainties, rising costs, decreasing volumes of COVID-19 tests, government regulations encouraging decentralized care adoption, the discovery of critical assays augmented with AI automation, digital integration, participation of nontraditional players in technology and retail, and more.

Key Issues Addressed:

  • Which critical strategic imperatives influence the US, Europe, and the UK’s diagnostic testing and service market?

  • What are the regulatory trends in the US, Europe, and the UK and their impact on the decentralized testing and service market?

  • What are the key segments, trends, market drivers, and restraints?

  • What is the new business model and its applications?

  • What is the decentralized testing and service market and the competitive landscape?

  • What are the key growth opportunities?

Author: Tejashri Manish Khadilkar

Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on Decentralized Testing and Service Market

Growth Opportunities Fuel the Growth Pipeline Engine™

Scope of Analysis

Segmentation

Key Trends in Decentralized Testing and Services

Key Trends in Decentralized Testing and Services (continued)

Growth Drivers

Growth Restraints

Key Regulatory Trends—US

Key Regulatory Trends—Europe–UK

Key Regulatory Policy Impact

Connected Health Everywhere

Competitive Landscape*

Growth Opportunity 1: Diagnostics as a Service in Newer Testing Sites

Growth Opportunity 1: Diagnostics as a Service in Newer Testing Sites (continued)

Growth Opportunity 2: Home-as-a-Smart Clinic

Growth Opportunity 2: Home-as-a-Smart Clinic (continued)

Growth Opportunity 3: Pharmacist-led Diagnostic Services in Rural Health Care

Growth Opportunity 3: Pharmacist-led Diagnostic Services in Rural Health Care (continued)

Growth Opportunity 4: Retinal Diagnostics in Preventable Blindness

Growth Opportunity 4: Retinal Diagnostics in Preventable Blindness (continued)

Abbreviations

Abbreviations (continued)

Abbreviations (continued)

List of Exhibits

Legal Disclaimer

List of Figures
  • Decentralized Testing and Services: Growth Drivers, US, Europe, and UK, 2023–2028
  • Decentralized Testing and Services: Growth Restraints, US, Europe, and UK, 2023–2028
  • Decentralized Testing and Services: End-user Sites and Applications, US, Europe, and UK, 2023–2028

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Life Sciences research

13 Jan 2025   |   Global   |   Market Outlook

Top 6 Growth Opportunities for the Digital Health Industry, 2025

Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...

17 Dec 2024   |   Global   |   Market Research

Cybersecurity in Healthcare, United States, 2024

Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...

12 Dec 2024   |   Global   |   Market Outlook

Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025

Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...

05 Dec 2024   |   Global   |   Frost Radar

Frost Radar™: Enterprise Conversational AI in Healthcare, 2024

This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-care, a...

27 Nov 2024   |   Global   |   Market Research

Generative AI in Payer and Provider IT Transformation, Global, 2024-2029

The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

Accelerated reforms due to COVID-19 and technologically advanced sample-in-answer-out portable, web-connected, encrypted devices that provide results in a few minutes changed the diagnostic healthcare industry. Decentralized testing empowers clinicians to make lifesaving decisions for the patient. It shortens supply chain lag time, saves costs of in-person clinical examination, reduces the length of hospital stay and wait lines, and helps improve access to rural and semi-urban settings for timely healthcare intervention. The next-generation point-of-care diagnostics is at an inflection point and is transforming patient care in emergency, acute, chronic, and specialized care with platforms capable of monitoring/measuring a wide range of disease markers with laboratory precision. The diagnostic innovation of assays for rapid detection, miniaturization of portable devices, and automation of workflows serves the broad spectrum of setting and shift toward hyper-scaling of access and comprehensive test designs. The study showcases several diagnostic technologies, such as a microfluidic-based hand-held portable device (lab-on-a-chip device) designed to provide atraumatic, end-to-end point-of-care automated and integrated diagnostic solution, with its sample-on-chip preparation and nucleic acid analysis assay. • The recent paper-based devices with Nucleic Acid Testing (NAT) have shown great promise for infectious diseases and detection etiology of infection (bacterial, viral, or fungal) with its cost-effective, bio-compatible, disposable on-site monitoring/testing. • Lateral flow devices with sensor technology enable rapid analysis of blood samples for many critical care assays. These include blood gases/electrolytes, cardiac markers, cholesterol/lipids, coagulation monitoring, glucose monitoring, hematology, infectious diseases, pregnancy and fertility, tumor/cancer markers, urinalysis, other chemistries (magnesium, lactate, micro-albumin, creatinine), and more. • Decentralized clinical diagnostics continue to innovate a wide range of systems and assays with rapid test analyzers, instruments, reagents, strips, and cartridges. The electronic services complement it with automation, cloud computing, and deep learning for rapid and accurate results. Digital technology is accelerating the adoption of decentralization in clinical practice as the workflows integrate with POC at-home systems delivering lab results on smartphones. Integrated, comprehensive diagnostic services are key differentiators for stakeholders, which vary in their offering to enterprises (labs, physician offices, or hospital emergency units) or patients. These services will enhance patient-centered access to care and help physicians close the diagnostic loop of the healthcare continuum. The regulatory environment analysis of the study provides insight into policies in the US, Europe, and the UK that are currently shaping the implementation of decentralized clinical diagnostics and influencing market adoption. The study, with an in-depth analysis of the industry environment and its participants, such as clinical laboratories, diagnostic/technology companies, retail, pharmacies, and start-ups, proposes a market model for connected healthcare and the prospective growth opportunities for stakeholders. Frost & Sullivan predicts the decentralized diagnostic testing market and services to grow exponentially in the next 5 years. This forecast considers structural shifts and economic uncertainties, rising costs, decreasing volumes of COVID-19 tests, government regulations encouraging decentralized care adoption, the discovery of critical assays augmented with AI automation, digital integration, participation of nontraditional players in technology and retail, and more.--BEGIN PROMO--

Key Issues Addressed:

  • Which critical strategic imperatives influence the US, Europe, and the UK’s diagnostic testing and service market

  • What are the regulatory trends in the US, Europe, and the UK and their impact on the decentralized testing and service market

  • What are the key segments, trends, market drivers, and restraints

  • What is the new business model and its applications

  • What is the decentralized testing and service market and the competitive landscape

  • What are the key growth opportunities

Author: Tejashri Manish Khadilkar

More Information
Deliverable Type Market Research
Author Tejashri Manish Khadilkar
Industries Healthcare
No Index No
Is Prebook No
List of Charts and Figures Decentralized Testing and Services: Growth Drivers, US, Europe, and UK, 2023–2028~ Decentralized Testing and Services: Growth Restraints, US, Europe, and UK, 2023–2028~ Decentralized Testing and Services: End-user Sites and Applications, US, Europe, and UK, 2023–2028~
Podcast No
WIP Number PE45-01-00-00-00

Trends and Growth Indicators for Physician Offices/labs in Decentralized Testing and Services

$2,450.00

Special Price $1,837.50 save 25 %

In stock
SKU
HC03631-NA-MT_27389